Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
393
Stocks News & Analysis
stocks
Are small caps finally back?
stocks
Chart of the Week: Modest earnings growth at odds with overvalued bank shares
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,329.10 | 50.90 | 0.55% |
CAC 40 | 8,225.78 | 18.91 | 0.23% |
DAX 40 | 24,207.79 | 56.66 | 0.23% |
Dow JONES (US) | 46,759.58 | 169.17 | 0.36% |
FTSE 100 | 9,578.57 | 63.57 | 0.67% |
HKSE | 25,967.98 | 186.21 | 0.72% |
NASDAQ | 22,965.46 | 225.07 | 0.99% |
Nikkei 225 | 48,641.61 | 666.18 | -1.35% |
NZX 50 Index | 13,377.10 | 70.66 | 0.53% |
S&P 500 | 6,744.12 | 44.72 | 0.67% |
S&P/ASX 200 | 9,032.80 | 46.60 | 0.52% |
SSE Composite Index | 3,922.41 | 8.65 | 0.22% |